AstraZeneca has faced a variety of ups and downs, leading to a fluctuating stock behaviour. The company's stock soared by almost
14% in six months, while some analysts indicate it may be a good time to buy. Setbacks, including failed drug trials, particularly in lung and breast cancer treatments, have seen the stock dip. Despite this, AstraZeneca reported riding out an oncology wave amid sector growth. However, Renaissance Technologies LLC and Point72 both decreased their interest, lowering their positions. Yet, some argue that AstraZeneca is an excellent growth investment and somewhat cheap. The company faced investigations in China over data and drug-import which affected its share performance. Despite some trials failing, CHMP endorsed AstraZeneca's Fasenra in a rare autoimmune disease, and some of their cancer drugs show promises, even smashing Q1 forecasts. Despite dips in stocks on disappointing trial results, their stocks have shown strides of improvement into growth. Furthermore, AstraZeneca plans to rake in $80 billion in total revenue by 2030, and a recent 'barely-disguised' dividend hike further ascertained investor confidence.
AstraZeneca Stocks News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sun, 29 Sep 2024 06:11:45 GMT -
Rating -2
- Innovation 6
- Information 8
- Rumor -4
